Dr Ludovic Juen, today presented a poster entitled, “A novel antibody-drug conjugate platform enabling high drug-to-antibody ratios and greater payload flexibility” at AACR 2023 in Orlando, Florida. We are delighted by the level of interest in the exciting new data presented and the potential for Spirea’s technology to transform the effectiveness and tolerability of ADCs.